µå·¯±×ÀÎÆ÷¸ÞÀÎ
 

»óº´Äڵ忡 µû¸¥ »óº´¸íÀ» È®ÀÎ ÇϽǼö ÀÖ½À´Ï´Ù.  
»óº´ÄÚµå ÇÑ±Û»óº´¸í ¿µ¹®»óº´¸í
Y428 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ³úÇϼöü Àü¿± È£¸£¸ó Anterior pituitary [adenohypophyseal] hormons causing adverse effects in therapeutic use
Y429 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ±âŸ ¹× »ó¼¼ºÒ¸íÀÇ È£¸£¸ó ±æÇ×Á¦ Other and unspecified hormone antagonists causing adverse effects in therapeutic use
Y43 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ÀÏÂ÷Àû Àü½ÅÁ¦Á¦ Primarily systemic agents causing adverse effects in therapeutic use
Y430 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â Ç׾˷¹¸£±â ¹× Ç×±¸ÅäÁ¦ Antiallergic and antiemetic drugs causing adverse effects in therapeutic use
Y431 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â Ç׾ϼº ´ë»ç¾ïÁ¦Á¦ Antineoplastic antimetabolites causing adverse effects in therapeutic use
Y431 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â »çÀÌŸ¶óºó Cytarabine causing adverse effects in therapeutic use
Y432 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â Ç׾ϼº õ¿¬¹° Antineoplastic natural products causing adverse effects in therapeutic use
Y433 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ±âŸ Ç×¾ÏÁ¦ Other antineoplastic drugs causing adverse effects in therapeutic use
Y433 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â Ç׾ϼº Ç×»ýÁ¦ Antineoplastic antibiotics causing adverse effects in therapeutic use
Y434 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ¸é¿ª¾ïÁ¦Á¦ Immunosuppressive agents causing adverse effects in therapeutic use
Y435 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â »ê¼ºÈ­Á¦ ¹× ¾ËÄ®¸®È­Á¦ Acidifying and alkalizing agents causing adverse effects in therapeutic use
Y436 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ´Þ¸® ºÐ·ùµÇÁö ¾ÊÀº È¿¼Ò·ù Enzymes, NEC causing adverse effects in therapeutic use
Y438 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ´Þ¸® ºÐ·ùµÇÁö ¾ÊÀº ±âŸ ÀÏÂ÷Àû Àü½ÅÁ¦Á¦ Other primarily systemic agents, NEC causing adverse effects in therapeutic use
Y438 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â Á߱ݼӱæÇ×Á¦ Heavy-metal antagonists causing adverse effects in therapeutic use
Y439 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â »ó¼¼ºÒ¸íÀÇ ÀÏÂ÷Àû Àü½Å¾à¹° Primarily systemic agent, unspecified causing adverse effects in therapeutic use
Y44 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ÀÏÂ÷ÀûÀ¸·Î Ç÷¾×¼ººÐ¿¡ ÀÛ¿ëÇÏ´Â Á¦Á¦ Agents primarily affecting blood constituents causing adverse effects in therapeutic use
Y440 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â öÁ¦Á¦ ¹× ±âŸ Ç×ÀúÇ÷»ö¼Ò¼º ºóÇ÷Á¦Á¦ Iron preparations and other anti-hypochromic-anemia preparations causing adverse effects in therapeutic use
Y441 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ºñŸ¹Î B12, ¿±»ê ¹× ±âŸ Ç×°Å´ëÀû¸ð±¸¼º ºóÇ÷ Á¦Á¦ Vitamin B12, folic acid and other anti-megaloblastic-anemia preparations causing adverse effects in therapeutic use
Y442 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â Ç×ÀÀ°íÁ¦ Anticoagulants causing adverse effects in therapeutic use
Y443 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â Ç×ÀÀ°í¼º ±æÇ×Á¦, ºñŸ¹Î K ¹× ±âŸ ÀÀ°íÁ¦ Anticoagulant antagonists, vitamin K and other coagulants causing adverse effects in therapeutic use
1901  1902  1903  1904  1905  1906  1907  1908  1909  [1910]